Novo Nordisk’s sickle cell therapy hits in Phase 3, but data lag expectations
诺和诺德的镰状细胞病疗法三期试验获阳性结果，但数据不及预期

Novo Nordisk said Monday that its sickle cell disease pill succeeded in a late-stage study. However, the data came in behind expectations the company set last year.
诺和诺德周一表示，其治疗镰状细胞病的口服药在一项晚期研究中取得成功。然而，这些数据不及公司去年设定的预期。